Pathwork picks up $20m for cancer test
This article was originally published in Clinica
Executive Summary
Sunnyvale, California-based Pathwork Diagnostics has raised $20m in its second round of financing led by Abingworth. The new capital will be used to support commercialisation of Pathwork's Tissue of Origin test for determining the origin of uncertain tumours. The product was cleared by the FDA in August. The company added that some of the new capital will also go towards new product development.
You may also be interested in...
Could Alcon's CyPass Trouble Be Boon For Glaukos – Or Bust For MIGS?
Minimally invasive glaucoma surgery specialist Glaukos saw its stock leap 40% in the wake of a worldwide recall by much bigger rival Alcon of its CyPass microstent.
Roche Dx' EMEA Head To Take Charge After Diggelmann Departs
Roland Diggelmann will end his decade-long career at Roche Diagnostics at the end of September. The business's head of EMEA Michael Heuer will take Diggelmann's place while the search is on for his replacement.
Nose For A Good Tech? Philips Adds Nasal Alar Pulse Oximetry To Monitoring Portfolio
Philips has added a new pulse oximetry platform to its patient monitoring portfolio, with the acquisition of Xhale Assurance.